232.98 USD
-6.50
2.71%
At close Feb 14, 4:00 PM EST
After hours
232.98
+0.00
0.00%
1 day
-2.71%
5 days
-2.51%
1 month
1.81%
3 months
0.67%
6 months
4.85%
Year to date
1.97%
1 year
29.04%
5 years
31.93%
10 years
250.72%
 

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 10,140

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

51% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 72

23% more capital invested

Capital invested by funds: $17.2B [Q2] → $21.2B (+$3.99B) [Q3]

22% more repeat investments, than reductions

Existing positions increased: 312 | Existing positions reduced: 255

4% more funds holding

Funds holding: 757 [Q2] → 784 (+27) [Q3]

2.06% less ownership

Funds ownership: 61.34% [Q2] → 59.28% (-2.06%) [Q3]

58% less call options, than puts

Call options by funds: $258M | Put options by funds: $619M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$250
7%
upside
Avg. target
$269
15%
upside
High target
$286
23%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
JP Morgan
David Low
0% 1-year accuracy
0 / 1 met price target
23%upside
$286
Overweight
Maintained
31 Jan 2025
Keybanc
Brett Fishbin
50% 1-year accuracy
9 / 18 met price target
20%upside
$280
Overweight
Maintained
31 Jan 2025
Piper Sandler
Adam Maeder
81% 1-year accuracy
13 / 16 met price target
12%upside
$260
Neutral
Maintained
31 Jan 2025
Stifel
Jonathan Block
21% 1-year accuracy
4 / 19 met price target
7%upside
$250
Hold
Initiated
13 Dec 2024

Financial journalist opinion

Based on 17 articles about RMD published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
Neutral
GlobeNewsWire
5 days ago
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies.
Jan De Witte joins GHO Capital as Operating Partner
Positive
Zacks Investment Research
6 days ago
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Positive
Seeking Alpha
6 days ago
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Negative
Zacks Investment Research
1 week ago
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
Positive
Zacks Investment Research
1 week ago
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neutral
Benzinga
1 week ago
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
Stock Of The Day: Trading The Range In ResMed
Positive
Zacks Investment Research
1 week ago
Here's Why ResMed (RMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why ResMed (RMD) is a Strong Momentum Stock
Positive
Zacks Investment Research
2 weeks ago
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
Neutral
Seeking Alpha
2 weeks ago
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™